Drugs / Mesenchymoangioblast-derived mesenchymal stem cells
Mesenchymoangioblast-derived mesenchymal stem cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02923375 | Mar 2017 → Aug 2018 | acute graft versus host disease | Cynata Therapeutics Limited | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mesenchymoangioblast-derived mesenchymal stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02923375 ↗ |
| Route | Intravenous | “Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001) at a dose of 1 million cells/kg (up to a maximum of 100 million cells) by IV infusion on two occasions (Day 0 and Day 7)” NCT02923375 ↗ |